Zydus Lifesciences, an Ahmedabad-based group, has announced the acquisition of UK-based LiqMeds Group for GBP 68 million (approximately Rs 689 crore). The acquisition will be made through Zydus Pharmaceuticals UK Ltd, a wholly-owned subsidiary of the group. In addition to the upfront consideration, Zydus will also make yearly earn-outs until 2026, contingent upon meeting certain agreed milestones related to the acquisition.
LiqMeds Group specializes in the development, manufacturing, and supply of oral liquid products for global markets. Its subsidiary, LM Manufacturing Ltd, operates an oral liquids manufacturing site in Weedon, Northampton, UK, which supplies products to the US and UK markets.
Zydus Lifesciences stated in a regulatory filing, “The upfront consideration of GBP 68 million will be supplemented yearly earn-outs until 2026, subject to the achievement of agreed milestones towards the acquisition of the LiqMeds Group of companies.” The transaction is expected to have a positive impact on Zydus’ earnings per share (EPS) from the first year of acquisition.
Managing Director of Zydus Lifesciences, Sharvil Patel, expressed the group’s belief in the potential of the liquid orals market, citing significant opportunities for new market expansion. The company aims to meet the unmet needs of geriatric and pediatric patients with oral liquid formulations, enhancing convenience and therapy compliance.
On the stock market, shares of Zydus were trading slightly lower, at Rs 574.70 per share on the BSE.
Zydus Lifesciences continues to demonstrate its commitment to growth and expansion, establishing a strong presence in the global market with strategic acquisitions and an innovative approach to patient-centric healthcare solutions.